Contraception for Women with Atrial Fibrillation on Anticoagulation
Primary Recommendation: Long-Acting Reversible Contraceptives (LARCs)
- The European Society of Cardiology recommends the levonorgestrel-releasing intrauterine device (LNG-IUD) as the safest and most effective contraceptive for women with cardiovascular disease, achieving pregnancy rates of <1% per year 1, 2, 3, 4.
- Intrauterine devices, including the LNG-IUD and copper IUD, have superior efficacy with failure rates of 0.2-0.8% per year, making them among the most effective reversible contraceptive methods available 6.
Contraindicated Methods
- The CDC classifies combined hormonal contraceptives as Category 4 (unacceptable health risk) for women with a history of deep venous thrombosis or pulmonary embolism on anticoagulation, due to increased thromboembolism risk 5, 7.
Alternative Options (Less Preferred)
- Progestin-only pills and depot medroxyprogesterone acetate (DMPA) are acceptable but less optimal, with typical-use failure rates of 3-8% per year, and should be used cautiously in patients with heart failure 1, 2, 3, 4, 5.
Important Clinical Considerations
- The European Society of Cardiology states that antibiotic prophylaxis is not recommended at the time of IUD insertion or removal in anticoagulated patients, as the risk of pelvic infection is not increased 1, 2, 3.